New spectacle lens shows promise for sharper vision in myopia

NCT ID NCT07668102

Completed Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a special lens called HAL for people with nearsightedness (myopia). 88 participants wore either the HAL lens or a standard single vision lens. Researchers measured reading speed and how well they could see at different distances and contrasts. The goal was to see if the HAL lens provides better vision performance than standard lenses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HAL spectacle lens
What this could lead to: If successful, this lens could offer better vision performance for people with myopia compared to standard single vision lenses.
What could go wrong: This is a small, completed study focused on vision performance, not long-term myopia control. Results may not apply to all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOPIA

Contacts and locations

Locations

Illinois College of Optometry

Chicago, Illinois, 60616, United States
Kannarr Eye Care

Pittsburg, Kansas, 66762, United States
New England College of Optometry

Boston, Massachusetts, 02115, United States
SUNY College of Optometry

New York, New York, 10036, United States
Sabal Eye Care

Longwood, Florida, 32779, United States
Sacco Eye Group

Vestal, New York, 13850, United States
Scripps Poway Optometry

San Diego, California, 92131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.